Cargando…
Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial
BACKGROUND: Stratified care is an up-to-date treatment approach suggested for patients with back pain in several guidelines. A comprehensively studied stratification instrument is the STarT Back Tool (SBT). It was developed to stratify patients with back pain into three subgroups, according to their...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393968/ https://www.ncbi.nlm.nih.gov/pubmed/30819162 http://dx.doi.org/10.1186/s12891-019-2467-6 |
_version_ | 1783398794783621120 |
---|---|
author | Karstens, Sven Krug, Katja Raspe, Heiner Wunderlich, Max Hochheim, Martin Joos, Stefanie Hüppe, Angelika |
author_facet | Karstens, Sven Krug, Katja Raspe, Heiner Wunderlich, Max Hochheim, Martin Joos, Stefanie Hüppe, Angelika |
author_sort | Karstens, Sven |
collection | PubMed |
description | BACKGROUND: Stratified care is an up-to-date treatment approach suggested for patients with back pain in several guidelines. A comprehensively studied stratification instrument is the STarT Back Tool (SBT). It was developed to stratify patients with back pain into three subgroups, according to their risk of persistent disabling symptoms. The primary aim was to analyse the disability differences in patients with back pain 12 months after inclusion according to the subgroups determined at baseline using the German version of the SBT (STarT-G). Moreover, the potential to improve prognosis for disability by adding further predictor variables, an analysis for differences in pain intensity according to the STarT-Classification, and discriminative ability were investigated. METHODS: Data from the control group of a randomized controlled trial were analysed. Trial participants were members of a private medical insurance with a minimum age of 18 and indicated as having persistent back pain. Measurements were made for the risk of back pain chronification using the STarT-G, disability (as primary outcome) and back pain intensity with the Chronic Pain Grade Scale (CPGS), health-related quality of life with the SF-12, psychological distress with the Patient Health Questionnaire-4 (PHQ-4) and physical activity. Analysis of variance (ANOVA), multiple linear regression, and area under the curve (AUC) analysis were conducted. RESULTS: The mean age of the 294 participants was 53.5 (SD 8.7) years, and 38% were female. The ANOVA for disability and pain showed significant differences (p < 0.01) among the risk groups at 12 months. Post hoc Tukey tests revealed significant differences among all three risk groups for every comparison for both outcomes. AUC for STarT-G’s ability to discriminate reference standard ‘cases’ for chronic pain status at 12 months was 0.79. A prognostic model including the STarT-Classification, the variables global health, and disability at baseline explained 45% of the variance in disability at 12 months. CONCLUSIONS: Disability differences in patients with back pain after a period of 12 months are in accordance with the subgroups determined using the STarT-G at baseline. Results should be confirmed in a study developed with the primary aim to investigate those differences. |
format | Online Article Text |
id | pubmed-6393968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63939682019-03-11 Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial Karstens, Sven Krug, Katja Raspe, Heiner Wunderlich, Max Hochheim, Martin Joos, Stefanie Hüppe, Angelika BMC Musculoskelet Disord Research Article BACKGROUND: Stratified care is an up-to-date treatment approach suggested for patients with back pain in several guidelines. A comprehensively studied stratification instrument is the STarT Back Tool (SBT). It was developed to stratify patients with back pain into three subgroups, according to their risk of persistent disabling symptoms. The primary aim was to analyse the disability differences in patients with back pain 12 months after inclusion according to the subgroups determined at baseline using the German version of the SBT (STarT-G). Moreover, the potential to improve prognosis for disability by adding further predictor variables, an analysis for differences in pain intensity according to the STarT-Classification, and discriminative ability were investigated. METHODS: Data from the control group of a randomized controlled trial were analysed. Trial participants were members of a private medical insurance with a minimum age of 18 and indicated as having persistent back pain. Measurements were made for the risk of back pain chronification using the STarT-G, disability (as primary outcome) and back pain intensity with the Chronic Pain Grade Scale (CPGS), health-related quality of life with the SF-12, psychological distress with the Patient Health Questionnaire-4 (PHQ-4) and physical activity. Analysis of variance (ANOVA), multiple linear regression, and area under the curve (AUC) analysis were conducted. RESULTS: The mean age of the 294 participants was 53.5 (SD 8.7) years, and 38% were female. The ANOVA for disability and pain showed significant differences (p < 0.01) among the risk groups at 12 months. Post hoc Tukey tests revealed significant differences among all three risk groups for every comparison for both outcomes. AUC for STarT-G’s ability to discriminate reference standard ‘cases’ for chronic pain status at 12 months was 0.79. A prognostic model including the STarT-Classification, the variables global health, and disability at baseline explained 45% of the variance in disability at 12 months. CONCLUSIONS: Disability differences in patients with back pain after a period of 12 months are in accordance with the subgroups determined using the STarT-G at baseline. Results should be confirmed in a study developed with the primary aim to investigate those differences. BioMed Central 2019-02-28 /pmc/articles/PMC6393968/ /pubmed/30819162 http://dx.doi.org/10.1186/s12891-019-2467-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Karstens, Sven Krug, Katja Raspe, Heiner Wunderlich, Max Hochheim, Martin Joos, Stefanie Hüppe, Angelika Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial |
title | Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial |
title_full | Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial |
title_fullStr | Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial |
title_full_unstemmed | Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial |
title_short | Prognostic ability of the German version of the STarT Back tool: analysis of 12-month follow-up data from a randomized controlled trial |
title_sort | prognostic ability of the german version of the start back tool: analysis of 12-month follow-up data from a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393968/ https://www.ncbi.nlm.nih.gov/pubmed/30819162 http://dx.doi.org/10.1186/s12891-019-2467-6 |
work_keys_str_mv | AT karstenssven prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial AT krugkatja prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial AT raspeheiner prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial AT wunderlichmax prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial AT hochheimmartin prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial AT joosstefanie prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial AT huppeangelika prognosticabilityofthegermanversionofthestartbacktoolanalysisof12monthfollowupdatafromarandomizedcontrolledtrial |